The career of Göran Ando, M.D., spans over 35 years and many executive roles at the most senior levels of numerous international pharma and biotech companies. Göran began his career in the pharmaceutical industry in 1978 and worked in increasingly senior roles within R&D of major pharmaceutical companies in the United States and United Kingdom, including Pfizer, Bristol Meyers and Glaxo. In 1995, Göran joined Pharmacia AB in Sweden as Executive Vice President and Deputy CEO, moving to the United States in 1997 to lead R&D with additional responsibilities for manufacturing, IT, business development and M&A. During his eight-year tenure as Head of R&D at Pharmacia/Pharmacia & Upjohn, 17 NCEs were approved by the US FDA. Most recently, Göran was CEO of Celltech Group PLC in the United Kingdom, one of the most successful European biotech companies, until it was acquired by UCB Pharma for $3 billion in 2005.
Göran has been serving since 2013 as the Chairman of the Board at Novo Nordisk A/S, Copenhagen and is also a Member of the Board of Directors of Novo A/S, Copenhagen. Novo Nordisk is the world’s leading pharmaceutical company focused on diabetes treatments with a market capitalization of over $100 billion, and Novo A/S is a holding and investment company with assets over $30 billion and the major shareholder in Novo Nordisk. Göran also serves as Chairman of the Board of Directors for Symphogen and is on the Board of Directors for Molecular Partners, both portfolio companies of Essex Woodlands. Previously, Göran has served as Chairman and board member of numerous private and public pharmaceutical and biotechnology companies. Göran is a Founding Fellow of the American College of Rheumatology in the United States.
Göran joined Essex Woodlands as Senior Advisor, based in the London office, in January 2007. Göran has a Bachelor of Arts degree from Uppsala University in Sweden as well as his Doctor of Medicine degree from Linkoeping University in Sweden and he still enjoys spending his summer holidays in the Stockholm archipelago.